These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11890362)

  • 1. Eziopitant. Pfizer.
    Evangelista S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1441-3. PubMed ID: 11890362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
    Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
    Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK-637. Takeda.
    Furness JB
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1437-40. PubMed ID: 11890361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behaviour in the rat.
    Tsuchiya M; Sakakibara A; Yamamoto M
    Eur J Pharmacol; 2005 Jan; 507(1-3):29-34. PubMed ID: 15659291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NN-414. Novo Nordisk.
    Choi JK
    Curr Opin Investig Drugs; 2003 Apr; 4(4):455-8. PubMed ID: 12808887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs.
    Obach RS
    Drug Metab Dispos; 2001 Dec; 29(12):1599-607. PubMed ID: 11717179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites.
    Reed-Hagen AE; Tsuchiya M; Shimada K; Wentland JA; Obach RS
    Biopharm Drug Dispos; 1999 Dec; 20(9):429-39. PubMed ID: 10951432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neurokinin-1 receptor antagonist that reduces intra-abdominal adhesion formation decreases oxidative stress in the peritoneum.
    Reed KL; Heydrick SJ; Aarons CB; Prushik S; Gower AC; Stucchi AF; Becker JM
    Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G544-51. PubMed ID: 17627972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol.
    Steensland P; Simms JA; Nielsen CK; Holgate J; Bito-Onon JJ; Bartlett SE
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis.
    Pittler MH; Ernst E
    Am J Gastroenterol; 1998 Jul; 93(7):1131-5. PubMed ID: 9672344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay of ezlopitant, a substance P receptor antagonist, and metabolites in biological matrices by gas chromatography with mass spectrometric detection: simultaneous analysis of a benzyl alcohol and alkene.
    Reed-Hagen AE; Janiszewski JS; Cole RO; Obach RS
    J Chromatogr B Biomed Sci Appl; 2000 Jul; 744(2):333-43. PubMed ID: 10993522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic therapy for the irritable bowel syndrome.
    Talley NJ
    Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
    Obach RS
    Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the degradation product of ezlopitant, a non-peptidic substance P antagonist receptor, by hydrogen deuterium exchange, electrospray ionization tandem mass spectrometry (ESI/MS/MS) and nuclear magnetic resonance (NMR) spectroscopy.
    Kamel AM; Zandi KS; Massefski WW
    J Pharm Biomed Anal; 2003 Apr; 31(6):1211-22. PubMed ID: 12667937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AN-2690, a novel antifungal for the topical treatment of onychomycosis.
    Barak O; Loo DS
    Curr Opin Investig Drugs; 2007 Aug; 8(8):662-8. PubMed ID: 17668368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of tegaserod for the treatment of irritable bowel syndrome.
    Bergmann K
    J Clin Pharm Ther; 2003 Apr; 28(2):151-3; author reply 153. PubMed ID: 12713613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.